Cystic Fibrosis Market

Market Overview: 

The cystic fibrosis market reached a value of USD 11,986.4 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 74,535.4 Million by 2035, exhibiting a growth rate (CAGR) of 18.1% during 2025-2035.

The cystic fibrosis market has been comprehensively analyzed in IMARC's new report titled "Cystic Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Cystic fibrosis is an inherited disorder that adversely affects the lungs, digestive system, pancreas, etc. It influences the cells that produce mucus, sweat, and digestive juices. People suffering from cystic fibrosis have defective genes that make digestive secretions thick and sticky and plug up ducts, passageways, and tubes, especially in the lungs and pancreas. The individuals who are not diagnosed until adulthood have milder diseases and experience symptoms like recurring incidences of an inflamed pancreas (pancreatitis), infertility, and pneumonia. Doctors may give drugs to open airways, thin mucus, prevent infections, and help the body get enough nutrients to fulfill its requirements. The other probable treatment options for cystic fibrosis are airway clearance techniques, vascular access devices, CFTCR modulators, surgical procedures, physical therapies, etc.

The rising prevalence of genomic mutations coupled with the increasing demand for effective medications that can treat such conditions is primarily driving the cystic fibrosis market. In addition to this, the shifting preferences of patients from intravenous therapy towards oral treatment options since they are cost-effective and less time-consuming are also propelling the market growth. Moreover, the emerging popularity of lentivirus gene therapy over conventional retroviral gene delivery systems owing to its several associated benefits, such as the ability to provide long-term and stable gene expression and to infect non-dividing cells, is also creating a positive outlook for the market. Besides this, the widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is bolstering the market growth. CFTRs are intended to regulate the flow of chloride and water through the cell linings of the lungs and rectify the malfunctioning protein in the body. Additionally, the ongoing development of personalized drug therapy, molecular prosthetics, and innovative drugs with improved efficacy is expected to drive the cystic fibrosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cystic fibrosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cystic fibrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cystic fibrosis market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cystic fibrosis market
• Historical, current, and future performance of various therapeutic categories in the cystic fibrosis market
• Sales of various drugs across the cystic fibrosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cystic fibrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cystic fibrosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the cystic fibrosis across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the cystic fibrosis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of cystic fibrosis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of cystic fibrosis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of cystic fibrosis by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of cystic fibrosis by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with cystic fibrosis across the seven major markets?
• What is the size of the cystic fibrosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend cystic fibrosis of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cystic fibrosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cystic fibrosis market?
• What are the key regulatory events related to the cystic fibrosis market?
• What is the structure of clinical trial landscape by status related to the cystic fibrosis market?
• What is the structure of clinical trial landscape by phase related to the cystic fibrosis market?
• What is the structure of clinical trial landscape by route of administration related to the cystic fibrosis market?